1-5 of 5
Muhit Ozcan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Huaqing Wang, Jifeng Feng, Tae Min Kim, Rong Tao, Huilai Zhang, Laura Fogliatto, Clara Maluquer Artigal, Muhit Özcan, Eduardo Yanez, Won Seog Kim, Dmitry Kirtbaya, Iryna Kriachok, Felipe Maciel, Hongwei Xue, Krimo Bouabdallah, Charles Phelps, Shalini Chaturvedi, Anke Weispfenning, Peter N. Morcos, Fatuma Odongo, Viktoriya Buvaylo, Barrett H. Childs, Martin Dreyling, Matthew Matasar, Paola Ghione
Journal: Blood Advances
Blood Adv (2024) 8 (18): 4866–4876.
https://doi.org/10.1182/bloodadvances.2024013236
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Clinical Trials & Observations
Loretta J. Nastoupil, Georg Hess, Miguel A. Pavlovsky, Iwona Danielewicz, Jane Freeman, Alejandro Martin García-Sancho, Valeria Glazunova, Andrew Grigg, Jing-Zhou Hou, Ann Janssens, Seok Jin Kim, Zvenyslava Masliak, Pam McKay, Francesco Merli, Wataru Munakata, Hirokazu Nagai, Muhit Özcan, Meir Preis, Tingyu Wang, Melissa Rowe, Monelle Tamegnon, Rui Qin, Todd Henninger, Madeliene Curtis, Donne Bennett Caces, Catherine Thieblemont, Gilles Salles
Journal: Blood Advances
Blood Adv (2023) 7 (22): 7141–7150.
https://doi.org/10.1182/bloodadvances.2023010298
Published: 2023
Includes: Supplemental data
Journal Articles

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Jose S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhit Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla
Journal: Blood Advances
Blood Adv (2022) 6 (2): 590–599.
https://doi.org/10.1182/bloodadvances.2021004970
Published: 2022
Includes: Supplemental data
Journal Articles

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Clinical Trials & Observations
Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar
Journal: Blood Advances
Blood Adv (2022) 6 (2): 533–543.
https://doi.org/10.1182/bloodadvances.2021005794
Published: 2022
Includes: Supplemental data
Journal Articles

Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Clinical Trials & Observations
Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro, Don Stevens, David Trevarthen, Florian Hiemeyer, Jose Garcia-Vargas, Barrett H. Childs, Pier Luigi Zinzani, Martin Dreyling
Journal: Blood Advances
Blood Adv (2021) 5 (3): 823–828.
https://doi.org/10.1182/bloodadvances.2020002910
Published: 2021
Includes: Supplemental data